Randomised controlled trial of nebulised budesonide vs oral prednisolone in acute severe asthma by Arulparithi, C S
DISSERTATION ON
RANDOMISED CONTROLLED TRIAL OF
NEBULISED BUDESONIDE VERSUS ORAL PREDNISOLONE
IN ACUTE SEVERE ASTHMA
Dissertation submitted to
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY 
in partial fulfillment of the requirement 
for the award of degree of  
MD BRANCH – VII
PAEDIATRIC MEDICINE
INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN
MADRAS MEDICAL COLLEGE
CHENNAI
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY, 
CHENNAI, TAMILNADU.
MARCH 2009
CERTIFICATE
     Certified that this dissertation entitled “Randomised Controlled Trial of Nebulised 
Budesonide Vs Oral Prednisolone In Acute Severe Asthma” is a bona fide work done by Dr. C.S. 
Arulparithi, Post graduate, Institute of Child Health and Hospital for Children, Madras Medical  
College, Chennai, during the academic year 2006-2009.
Prof. Dr. SARADHA SURESH,  
M.D., Ph.D., F.R.C.P. (Glas),  
Director and Superintendant, 
Institute of Child Health & Hospital for 
Children,
HOD and Professor of Pediatrics,
Madras Medical College,
Chennai – 600 003.
Prof.  Dr. P. PARAMANANDHAM, M.D., 
D.C.H., Ph.D., (NEO),
Professor of Pediatrics,
Institute of Child Health & Hospital for 
Children,
Madras Medical College,
Chennai – 600 003.
Prof. Dr. T. P. KALANITI, M.D.,
Dean,
Madras Medical College, Chennai
ACKNOWLEDGEMENT
I express my sincere thanks to Prof. Dr. T. P. KALANITI, M.D., Dean, Madras Medical 
College for allowing me to do this dissertation and utilize the institutional facilities.
I express my sincere and heartfelt gratitude to Prof. Dr. SARADHA SURESH, M.D., Ph.D., 
F.R.C.P. (Glas), Director and Superintendent, Institute of Child Health and Hospital for Children, for 
her invaluable guidance and support. 
I am extremely thankful to Prof. Dr. P. PARAMANANDHAM, MD., D.C.H., Ph.D., (NEO), 
Professor of Pediatrics, Institute of Child Health and Hospital for Children, Chennai for his invaluable 
help and guidance.
I would like to thank Dr C. RAVICHANDRAN, Assistant Professor of Pediatrics,  Institute of 
Child Health and Hospital for Children for initiating this topic and encouraging me throughout the 
study. I am very grateful to him for his invaluable guidance and support from the beginning to the end 
of the study.
I would like to specially thank DR. INDUMATHY SANTHANAM, Assistant Professor, 
Pediatric Emergency Medicine Department, Institute of Child Health and Hospital for Children, for her 
constant encouragement and invaluable guidance throughout my study. This study would not have been 
possible without her good support and encouragement.
I would to like to thank Dr. B. SATHYAMURTHI, Dr. S. PARIVATHINI, and Dr. J. 
HEMACHITRA for their help and support throughout my study. I would like to specially thank all my 
colleagues for their constant encouragement and support. I am greatly indebted to all the children who 
participated in this study and their parents without whom this study would not have been possible.
                                    CONTENTS
S.№ TITLE PAGE №
1. INTRODUCTION 1
2. REVIEW OF LITERATURE 19
3. JUSTIFICATION OF  STUDY 27
4. AIM OF THE STUDY 30
5. METHODS 31
6. RESULTS 40
7. DISCUSSION 52
8. CONCLUSION 56
9. RECOMMENDATION 57
10. ANNEXURE 1 – DATA COLLECTION 
FORM
11. ANNEXURE 2 – REFERENCES
Introduction
Asthma has been recognized as a disease since the earliest times. In the Corpus Hippocraticum, 
Hippocrates used the term “ασθμα” to indicate any form of breathing difficulty manifesting itself by 
panting. Aretaeus of Cappadocia, a well-known Greek physician (second century A.D.), is credited 
with providing the first detailed description of an asthma attack1.
DEFINITION2
Asthma is a common chronic disorder of the airways that is complex and characterized by variable 
and  recurring  symptoms,  airflow  obstruction,  bronchial  hyperresponsiveness,  and  an  underlying 
inflammation.  The interaction of these features of asthma determines the clinical manifestations and 
severity of asthma (figure1) and the response to treatment.
Figure 1 THE INTERPLAY AND INTERACTION BETWEEN AIRWAY INFLAMMATION AND THE 
CLINICAL SYMPTOMS AND PATHOPHYSIOLOGY OF ASTHMA2
CHARACTERISTICS  OF  CLI  NICAL 
ASTHMA2
• Symptom
• Airway obstruction
• Inflammation
• Hyperresponsiveness
EPIDEMIOLOGY3
Asthma is one of the most common chronic diseases in the world. It is estimated that around 
300 million people in the world currently have asthma. Considerably higher estimates can be obtained 
with less conservative criteria for the diagnosis of clinical asthma. Asthma has become more common 
in both children and adults around the world in recent decades.
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Globally, childhood asthma prevalence varies widely in different locales. A large international 
survey study of  childhood asthma prevalence  in  56  countries  (International  Study  of  Asthma and 
Allergies in Childhood) found a wide range in asthma prevalence, from 1.6 to 36.8%. In India, a tenfold 
variation in the prevalence of childhood asthma has been observed. 
There has been a marked increase in the prevalence of asthma in Southern Asia (Bangladesh, 
Bhutan, India, Nepal, Seychelles, and Sri Lanka) over the last two decades with up to threefold increase 
in children. The region’s industrialisation and urban growth is occurring at an unprecedented rate in 
what was previously a predominately agrarian society. India is projected to become the world’s most 
populous nation by the year 2050. As a result, further predicted increase in the prevalence of asthma 
will result in a marked increase in the number of asthmatics. The levels of air pollution in cities in the 
region are well above the permissible levels recommended by national and international guidelines.
In  view  of  the  well  documented  association  between  high  levels  of  air  pollution  and 
exacerbations  of  asthma,  and  the  important  role  of  air  pollution  as  a  risk  factor  contributing  to 
respiratory  and  all-cause  mortality,  reducing  the  level  of  air  pollution  remains  one  of  the  most 
important public health priorities in Southern Asia. Indoor air pollution remains a major risk factor for 
respiratory disease, including asthma.
PATHOPHYSIOLOGY AND PATHOGENESIS OF ASTHMA2
Airflow limitation in asthma is recurrent and caused by a variety of changes in the airway.
 Bronchoconstriction
 Airway edema
 Airway hyperresponsiveness
 Airway remodelling
PATHOPHYSIOLOGIC MECHANISMS IN THE DEVELOPMENT OF AIRWAY 
INFLAMMATION2
Inflammation has a central role in the pathophysiology of asthma. As noted in the definition of 
asthma, airway inflammation involves an interaction of many cell types and multiple mediators with 
the  airways  that  eventually  results  in  the  characteristic  pathophysiological  features  of  the  disease: 
bronchial inflammation and airflow limitation that result in recurrent episodes of cough, wheeze, and 
shortness of breath. The pattern of airway inflammation in asthma, however, does not necessarily vary 
depending upon disease severity,  persistence,  and duration of disease.  The cellular  profile  and the 
response of the structural cells in asthma are quite consistent.
FIGURE 2  AIRWAY INFLAMMATION2
 Inhaled antigen activates mast cells and Th2 cells in the airway. They in turn induce the production of  
mediators of Inflammation (such as histamine and leukotrienes) and cytokines including interleukin-4  
and interleukin-5.  Interleukin-5 travels  to  the  bone marrow and causes  terminal  differentiation of  
eosinophils. Circulating eosinophils enter the area of allergic inflammation and begin migrating to the  
lung by rolling, through interactions with selectins, and eventually adhering to endothelium through 
the binding of integrins to members of the immunoglobulin superfamily of adhesion proteins: vascular-
cell  adhesion  molecule  1  (VCAM-1)  and  intercellular  adhesion  molecule  1  (ICAM-1).  As  the  
eosinophils enter the matrix of the airway through the influence of various chemokines and cytokines,  
their  survival  is  prolonged by interleukin-4 and granulocyte-macrophage colony-stimulating factor  
(GM-CSF). On activation, the eosinophil releases inflammatory mediators, such as leukotrienes and 
granule proteins, to injure airway tissues. In addition, eosinophils can generate GM-CSF to prolong  
and potentiate their survival and contribution to persistent airway inflammation. MCP-1, monocyte 
chemotactic protein; and MIP-1α, macrophage inflammatory protein.
PATHOGENESIS2
The expression of asthma is a complex, interactive process that depends on the interplay between 
two major factors—host factors (particularly genetics) and environmental exposures that occur at a 
crucial time in the development of the immune system.
In summary, our understanding of asthma pathogenesis and underlying mechanisms now includes 
the concept that gene - environmental interactions are critical factors in the development of airway 
inflammation  and eventual  alteration  in  the  pulmonary physiology that  is  characteristic  of  clinical 
asthma2.
ROLE OF CORTICOSTEROIDS IN MANAGEMENT OF ASTHMA
The NAEPP (National Asthma Education and Prevention Program)2 guidelines recommend daily 
Inhaled Corticosteroid therapy as the treatment of choice for all patients with persistent asthma. Inhaled 
Corticosteroids therapy has been shown to reduce asthma symptoms, improve lung function, reduce 
AHR (Airway hyperresponsiveness),  reduce  “rescue”  medication  use  and,  most  important,  reduce 
urgent  care  visits,  hospitalizations,  and  prednisolone  use  for  asthma exacerbations  by about  50%. 
Systemic  corticosteroids  either  orally  or  parenterally  has  been  used  in  the  management  of  acute 
exacerbation of asthma. Opposed, inhaled corticosteroids (ICS) have been considered ineffective in 
treatment of acute exacerbations of asthma. Nevertheless, many studies published in the past 15 yrs 
have  showed  therapeutic  early  effects  (after  minutes  of  its  administration)  suggesting  different 
mechanism of action of topical character (non-genomic).
Inhaled corticosteroids suppress airway inflammation and components of airway 
remodelling in bronchial asthma. In the tracheobronchial (airway) vasculature, these 
include the inhibition of inflammatory hyperperfusion, microvascular hyperpermeability, 
mucosal oedema formation, and the formation of new blood vessels (angiogenesis). 8
Corticosteroids  are now known to  exert  their  effects  on the airway vasculature 
through  genomic  and  non-genomic  mechanisms. Genomic  actions  involve  the 
regulation  of  target  genes,  and suppress  most  of  the  vascular  elements  of 
inflammation and angiogenesis in the airway.  In contrast,  non-genomic actions are 
mediated by rapid cellular mechanisms, and induce transient vasoconstriction in the 
airway, thereby reversing inflammatory hyperperfusion8. 
The vascular actions of corticosteroids contribute to controlling clinical symptoms 
of  asthma primarily  by influencing airway calibre  in  the  lung  periphery  and airway 
hyperreactivity. 
GENOMIC EFFECTS OF CORTICOSTEROIDS
Systemic Corticosteroids (SCS) act by reducing airway inflammation. Systemic Corticosteroids 
require 4 to 24 hrs to improve pulmonary function and reduce hospitalisations4. This time delay is due 
to the proposed mechanism of action of Systemic Corticosteroids i.e. gene transcription and altered 
protein synthesis (see figure 3). Genomic actions involve the regulation of target genes, and suppress 
most  of  the  vascular  elements  of  inflammation  and  angiogenesis  in  the  airway8.  Corticosteroids 
increase the synthesis  of anti-inflammatory proteins or inhibit  the synthesis  of many inflammatory 
proteins through suppression of the genes that encode them. This genomic effect  may take several 
hours or days.
FIGURE 3 CLASSIC (GENOMIC) MODEL OF GLUCOCORTICOID ACTION6 
The glucocorticoid enters the cell  and binds to a cytoplasmic glucocorticoid receptor (GR) that is  
complexed with two molecules of a 90-kD heat shock protein (hsp 90)2. Glucocorticoid Receptor then 
translocates to the nucleus where, as a dimer, it binds to a glucocorticoid recognition sequence (GRE) 
on the 5'-upstream promoter sequence of steroid-responsive genes. GREs may increase transcription 
and nGREs may decrease transcription, resulting in increased or decreased messenger RNA (mRNA)  
and protein synthesis.
RAPID NON-GENOMIC EFFECTS OF CORTICOSTEROIDS4
Although  the  major  anti-inflammatory  effects  of  corticosteroids are  due  to  transcriptional 
mechanisms, evidence is growing for actions manifested within seconds or minutes. These effects are 
mediated by cellular mechanisms that are too rapid to involve gene expression and have been termed 
non-genomic actions. Non-genomic actions are initiated by specific interactions with membrane-bound 
or Cytoplasmic GRs (Glucocorticoid receptors), or nonspecific interactions with the cell membrane8.
Most  recently  research  has  been  focussed  on  these  rapid  non-genomic  effects  of  Inhaled 
Corticosteroids (ICS) on airway smooth muscle tone and in decreasing airway blood flow by altering 
vascular tone. Asthmatics show a significant increase in mucosal blood flow compared with healthy 
subjects. Inhalation of corticosteroids decreases airway blood flow by modulating sympathetic control 
of vascular tone. Corticosteroids inhibit the uptake of norepinephrine thereby increasing norepinephrine 
concentration  at  the  neuromuscular  junction  hence  inducing  vasoconstriction  (see  figure  4).  This 
enhances the action of inhaled bronchodilators by diminishing their clearance from the airways. Thus 
simultaneous administration of Inhaled Corticosteroids and bronchodilators results in greater effects.
In summary corticosteroids show two different effects on acute asthma patients (see figure 5),
1. the  classical  anti-inflammatory  or  genomic  action ,  involving  modification  of  gene 
expression, that occurs with a time lag of hours or days
2. the non-genomic action with a rapid onset (minutes), is reversible (short duration) and is 
dose-dependent.
FIGURE 4  RAPID NON – GENOMIC ACTION OF CORTICOSTEROIDS8  
Proposed mechanism of action of the acute vasoconstrictor effect  of  inhaled corticosteroids in the 
airway.  Corticosteroids  facilitate  the  sympathetic  neuromuscular  signal  transmission  by  rapidly 
(within 5 min) inhibiting the extraneuronal  monoamine transporter (EMT) in  the vascular smooth  
muscle cells.
Inhaled Corticosteroids would have to be administered simultaneously with bronchodilators in 
high and repeated or sequential  doses to obtain and maintain the effect throughout the time. Since 
Inhaled  Corticosteroids  induced  vasoconstriction  peaks  between  30  and  60  min  after  drug 
administration, they should be administered at intervals of 30 min or less.
FIGURE  5  SCHEMATIC  DIAGRAM  OF  THE  COMPLEX  CELLULAR  ACTIONS  OF 
CORTICOSTEROIDS
Genomic actions are mediated by cytoplasmic receptors, which ultimately alter transcription through  
A) direct DNA binding or B) transcription factor inactivation. In contrast, non-genomic actions are  
mediated by C) membrane-bound or D) cytoplasmic receptors, or E) nonspecific interactions with the  
cell membrane. cGR: cytoplasmic glucocorticoid receptor; mGR: membrane glucocorticoid receptor;  
LBD:  ligand-binding  domain;  DBD:  DNA-binding  domain;  Hsp90:  heat-shock  protein  90;  RE: 
response element; NF- B: nuclear factor- B; AP-1: activating protein-1
TABLE 1 GENOMIC AND NON-GENOMIC ACTION OF CORTICOSTEROIDS4
Variables Genomic Non-genomic
Receptor location Cytoplasmic Membrane
Onset Slow (hrs to days) Rapid (sec to mts)
Actions Regulation of inflammatory gene 
transcription
Inhibition of local catecholamine 
disposal
Target-effects Angiogenesis: ↓ vessel density
Hyperperfusion: ↓
Hyperpermeability: ↓
Leukocyte recruitment: inhibition
Hyperperfusion: ↓
Reduction of airway blood flow by different corticosteroids
Corticosteroids exert rapid, delayed, and long-term effects on the airway vasculature in asthma. 
Among these effects, corticosteroids have been shown to acutely (within minutes) alter vascular tone 
through non-genomic cellular actions.
Inhaled corticosteroids have been shown to acutely suppress airway hyperperfusion associated 
with  asthma.  A  single  dose of  inhaled  fluticasone  propionate  has  been  shown to  decrease airway 
mucosal blood flow in healthy and asthmatic subjects with a maximal effect 30 min after inhalation, 
and a return to baseline at 90 min. The blood flow effect increased in a dose-dependent manner up to 
880 µg  of  fluticasone propionate,  with  a  significantly  greater  effect  in  asthmatics than  in  healthy 
controls.  The  acute  vasoconstrictor  action  has also  been  demonstrated  after  inhalation  of 
beclomethasone dipropionate and budesonide.
FIGURE  6  Rapid (#), delayed (¶), and long-term (+) vascular effects of inhaled 
corticosteroids in the airway of patients with asthma. Effects are spaced vertically on 
the y-axis simply to facilitate reading. 
In  summary,  the  complex  vascular  actions  of  corticosteroids  suggest  that asthma-associated 
angiogenesis,  hyperperfusion,  hyperpermeability, and  leukocyte  recruitment  are  anti-inflammatory 
targets.  The recently demonstrated rapid non-genomic actions of corticosteroids on airway vascular 
smooth muscle open new avenues for additional interventions in the pharmacotherapy of asthma. 
COMPARATIVE BRONCHIAL VASOCONSTRICTIVE EFFICACY OF 
INHALED GLUCOCORTICOSTEROIDS5
The standard screening test to determine the relative "potencies" for inhaled corticosteroids has 
been  the  McKenzie  skin  blanching  test21.  However,  this  procedure  has  come under  criticism.  The 
intensity of the blanching response to a glucocorticoid varies from subject-to-subject and is influenced 
by ambient temperature and humidity and other factors.
Using a soluble, inert gas-uptake method to measure airway blood flow (Qaw)5,  it was found 
that inhaled fluticasone propionate and budesonide caused greater vasoconstriction in the airway than 
beclomethasone  dipropionate  (see  figure  9).  It  was  also  shown  that  for  all  three  inhaled 
glucocorticosteroids, the vasoconstrictor response is greater in asthmatics than in healthy subjects
BUDESONIDE 7
Underutilization  of  anti-inflammatory  agents  in  the  treatment  of  asthma  has  received 
widespread attention. Inhaled glucocorticosteroids are important agents for the management of asthma 
in children and adults. Budesonide has a high ratio of topical anti-inflammatory to systemic activity and 
is one of the most extensively used inhaled glucocorticoids.
FIGURE  7  LOCAL  PHARMACOKINETICS  OF  INHALED  CORTICOSTEROIDS 
DEPOSITED IN THE AIRWAYS6.
First the drug has to become dissolved in the watery layer on the surface of the epithelium. Then it  
is absorbed into the cell where it exerts its action. Budesonide seems to be retained longer than other 
steroids because it forms conjugates with long-chain fatty acids within cells (410). These fatty acids  
typically oleic acid bind reversibly to the budesonide molecule; such conjugation does not appear to 
occur with BDP, FP, or hydrocortisone. Budesonide fatty acid conjugates appear to act as an 
intracellular store of inactive budesonide. Only free budesonide binds at the glucocorticoid receptor 
(GR), but as the airways concentration of free budesonide decreases, lipase enzymes in mucosal 
airway cells release more of the free compound from its conjugated fatty acids, thus raising the level of  
budesonide available for receptor binding.                              
Budesonide is a nonproteolytic, moderately lipophilic compound with rapid uptake into airway 
mucosa.  Budesonide is a potent topical glucocorticoid with a favorable ratio between topical anti-
inflammatory activity and systemic corticosteroid effects when administered by inhalation in patients 
with asthma. Therapeutic benefits of inhaled budesonide are explained primarily by its local effects in 
the  lung.  Inhaled  budesonide  has  been  shown  to  reduce  the  number  of  inflammatory  cells  and 
mediators present in the airways of patients with asthma. In addition, inhaled budesonide has been 
shown to decrease airway hyperresponsiveness after histamine, methacholine, and allergen challenges 
in children with asthma.
The  pharmacokinetics of BIS (Budesonide inhalation suspension) administered by nebulisation 
has been well characterized in children. Only jet nebulizers are recommended for administration of 
BIS. Absorption of nebulised budesonide from the lungs is rapid, with peak plasma concentrations 
reached approximately 10 to 30 minutes after the start of nebulisation (see figure 8). The budesonide 
deposited  in  the  oropharynx  is  assumed  to  be  swallowed  and  eventually  absorbed  from  the 
gastrointestinal  tract;  however,  because  of  extensive  first-pass  elimination  of  oral  budesonide 
(approximately 85%-90%), very little drug is systemically absorbed. In 3- to 6-year-old children with 
asthma, the total systemic availability (pulmonary plus oral) of BIS (Budesonide inhalation suspension) 
by a jet nebulizer was approximately 6% of the labeled dose. 
In children 3 to 6 years of age, nebulisation of BIS 1 mg, using jet nebulizer-compressor systems 
that deliver between 5% and 17.8% of the labelled budesonide dose in vitro are expected to deliver a 
clinically effective dose.
Overall, the pharmacokinetic profile of BIS (Budesonide inhalation suspension) allows for a long 
duration  of  local  therapeutic  effects  (see  figure  7)  with  minimal  systemic  exposure.  This  novel 
formulation of budesonide is a long-awaited therapeutic option for the treatment of persistent asthma in 
infants and children.
FIGURE 8 BIS (Budesonide inhalation suspension) plasma concentration-time data in children 3 
to 6 years of age (n = 10)9
REVIEW OF LITERATURE
Gustavo  J.  Rodrigo,  MD,  Emergency  Department,  Hospital  Central  de  las,  Montevideo, 
Uruguay conducted a meta analysis of the best evidence available on the early (1 to 4 h) clinical impact 
of Inhaled Corticosteroids for patients with acute asthma in the emergency department (ED) setting. 
He reviewed seventeen randomised controlled trials  (470 adults  and 663 children and adolescents) 
conducted between the period of  1966 to  2006.  His  review suggested that  Inhaled Corticosteroids 
present early beneficial effects (1 to 2 h) when they were used in multiple doses administered in time 
intervals ≤ 30 min over 90 to 120 min. The non-genomic effect is a possible candidate by covering the 
link between molecular pathways and the clinical effects of corticosteroids4.
Van Essen-Zandvliet  et  al.’  showed an  improvement  in  FEV, within  5 hours  after  inhaled 
budesonide was given to children aged 7 to 13 years with mild stable asthma.
Schuh et al, Division of Paediatric Emergency Medicine, Hospital for Sick Children, Ontario, 
Canada conducted a randomised, double-blind controlled trial called “High-Dose Inhaled Fluticasone 
Does  Not  Replace  Oral  Prednisolone  in  Children  With  Mild  to  Moderate  Acute  Asthma”.  They 
determined whether there is a significant difference in the percentage of predicted forced expiratory 
volume  in  1  second  in  children  with  mild  to  moderate  acute  asthma  treated  with  either  inhaled 
fluticasone  or  oral  prednisolone.  The  study was  conducted  between  2001  and  2004  involving  69 
previously healthy children 5 to 17 years of age with acute asthma and forced expiratory volume in 1 
second at 50% to 79% predicted value. The study concluded that airway obstruction in children with 
mild to moderate acute asthma in the emergency department improves faster on oral prednisolone than 
inhaled fluticasone10.
Rowe BH et al, Department of Emergency Medicine, University of Alberta, Edmonton, Canada 
et al conducted a review of Randomised controlled trials to evaluate the benefits of “Early emergency 
department  treatment of  acute asthma with systemic corticosteroids”.  The study found that  use of 
corticosteroids  within  1  hour  of  presentation  to  an ED significantly reduces  the  need  for  hospital 
admission in patients with acute asthma. Benefits appear greatest in patients with more severe asthma, 
and those not currently receiving steroids. Children appear to respond well to oral steroids11.
A Randomised Controlled Trial of “Inhaled Flunisolide in the Management of Acute Asthma in  
Children” conducted by Albert K. Nakanishi, From the Department of Pediatrics (Dr. Nakanishi), St. 
Louis University School of Medicine, St. Louis, found that inhaled corticosteroids are useful in the 
management of acute asthma in children; however, spirometry data suggested a more rapid resolution 
of asthma with Oral Corticosteroids12. 
EE  Matthews,  MD  Princess  Royal  Hospital,  Apley  Castle,  Telford,  UK  in  a  prospective, 
double-blind,  randomised controlled study of  “Nebulised budesonide versus oral  steroid in severe  
exacerbations  of  childhood  asthma”  compared  nebulised  budesonide  (2  mg  8  hourly)  with  oral 
prednisolone (2 mg/kg at  entry and again at  24 h) in 46 children admitted to hospital  with severe 
asthma exacerbations. Efficacy variables (including lung function measurements such as the primary 
outcome variable, Forced Expiratory Volume in 1 second (FEV1) and symptoms) were measured 24 h 
after treatment initiation. The data show nebulised budesonide to be at least as effective as oral steroid 
in improving lung function and symptom severity in severe exacerbations of childhood asthma13.
 
Lillian Sung, MD, et al   conducted a “Randomised, Controlled Trial of Inhaled Budesonide as  
an Adjunct to Oral Prednisone in Acute Asthma “.  They compared the clinical effect of nebulised 
budesonide  with  placebo  in  acute  pediatric  asthma  at  the  Children’s  Hospital  of  Eastern  Ontario, 
University of Ottawa, Canada. They found no significant differences in the primary outcome measure 
(PIS - Pulmonary Index Score) between the 2 groups. However, the PIS at 1 hour had a tendency to be 
lower in the budesonide group (median = 5) as compared with the placebo group (median = 6; p = 
0.07). Survival analysis of release/discharge from the ED showed a more rapid rate in the budesonide 
group as compared with the placebo group (p = 0.02). No adverse effects were seen14. 
Edmonds et al conducted a systematic review of the literature with meta-analysis to determine 
the benefit of inhaled Corticosteroids for the treatment of patients with acute asthma managed in the 
emergency department. On the basis of six randomised controlled trials (six adult, two pediatric), the 
authors found that patients treated with inhaled Corticosteroids were less likely to be admitted to the 
hospital (odds ratio, 0.33; 95% confidence interval, 0.17 to 0.64); additionally, they demonstrated a 
significant improvement in FEV1 at 2 h of treatment15. 
In a Randomised double-blind, double-dummy and placebo-controlled clinical trial evaluating 
the efficacy of “Nebulised budesonide to treat acute asthma in children” Geórgia K. M. Milani found 
that a combination of single-dose nebulised budesonide and salbutamol may be as effective as oral 
prednisone  to  improve  symptom  severity,  but  the  latter  increases  haemoglobin  saturation  in 
exacerbation of asthma16.
Devidayal,  Singhi  S,  et  al  from the  Department  of  Pediatrics,  Advanced Pediatrics  Centre, 
Postgraduate Institute of Medical Education and Research, Chandigarh, India evaluated the “Efficacy 
of  nebulised budesonide  compared to  oral  prednisolone  in  acute  bronchial  asthma”.  The baseline 
characteristics of the two groups were similar, but after three doses of nebulisation oxygen saturation, 
respiratory rate,  pulmonary index and respiratory distress score were significantly improved in the 
budesonide group compared to prednisolone group (p < 0.01). The proportion of patients who were fit 
for discharge at  the end of 2 h after  the third dose of nebulisation was significantly higher in the 
budesonide group than in the prednisolone group (22/ 41, 54% vs 7/39, 18%, p < 0.001). The data 
suggest  that  a  combination  of  nebulised  salbutamol  and  budesonide  should  be  preferred  in  the 
emergency room management of children with acute moderate to severe exacerbation of asthma and 
who are not on prior oral or inhaled steroid therapy17.
In a study done by E.S.Mendes et al, Pulmonary and Critical Care Division, Dept of Medicine, 
University of Miami, FL, USA a soluble, inert gas-uptake method was used to measure airway blood 
flow  (Qaw)6.   Mendes,  E.S.,  Pereira  et  al  (2003)  did  a  study  on  “Comparative  bronchial  
vasoconstrictive efficacy of inhaled glucocorticosteroids”. In summary, this investigation showed that 
inhaled  fluticasone  propionate  and  budesonide  cause  greater  vasoconstriction  in  the  airway  than 
beclomethasone  dipropionate  (see  figure  9).  It  was  also  shown  that  for  all  three  inhaled 
glucocorticosteroids, the vasoconstrictor response is greater in asthmatics than in healthy subjects5. 
FIGURE  9—  Airway  blood  flow  (Qaw)  before  and  after  the  inhalation  of  fluticasone  (•), 
beclomethasone  ( )  and budesonide  ( )  in  asthmatic  subjects  (n=10).  Data  are  presented as 
mean±sd. *: p<0.05 versus baseline value5
These  findings  indicate  drug-specific  and  disease-specific  in  vivo  potency differences  in  both 
bioavailability  and  vasoconstrictive  efficacy  among  three  commonly  prescribed  glucocorticoid 
metered-dose  inhalers.  The  relative  vasoconstrictive  efficacies  of  Beclomethasone,  Fluticasone  and 
Budesonide were 1, 1.9 and 2.7, respectively, in asthmatic subjects and 1, 3.3 and 3.0, respectively, in 
healthy subjects.
FIGURE 10 Dose/response relationship between inhaled fluticasone(•), beclomethasone ( ) and 
budesonide ( ) dose and airway blood flow (Qaw) in asthmatics (n=10). Data are presented as 
mean±sd. : p<0.05 versus baseline value5
De Blic J, et al evaluated the  “Efficacy of nebulised budesonide in treatment of severe infantile  
asthma” in  a double-blind, placebo-controlled study, where 40 infants with severe asthma received 
either nebulised budesonide (1 mg) or placebo twice daily for 12 weeks, followed by a follow up period 
of up to 12 weeks.. Significantly fewer patients in the budesonide group had exacerbations requiring 
administration of oral corticosteroids, and for those who had such exacerbations, the duration of oral 
corticosteroid therapy decreased. The incidence of daytime and night time wheezing was lower in the 
budesonide group than in the placebo group. He therefore concluded that nebulised budesonide (1 mg 
twice  daily)  is  a  well-tolerated  and efficient  treatment  for  severe  infantile  asthma (J_Allergy Clin 
Immunol 1996; 98.'14-20.) 18.
Volovitz  B,  et  al  From the  Asthma  Clinic,  Department  of  Pediatrics  ,  Schneider  Children’s 
Medical  Center  of  Israel,  Tel  Aviv  University  (1998) did  a  controlled  comparative  study  on 
“Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children 
who were treated in the emergency department compared with oral prednisolone”. In conclusion, this 
study shows that in children with moderately severe asthma attacks who were treated in the ED, a 
short-term dose schedule of inhaled budesonide given by means of turbohaler, starting with a high dose 
and followed by a rapid decrease in dose over 8 days, is at  least  as effective as oral  prednisolone 
treatment without the suppression of serum cortisol levels19.
Manjra, et al  Paediatric Allergy and Asthma Centre, Westville Hospital, Westville, South Africa 
(2000) designed a multi-centre, randomised, double-blind, study to compare the Efficacy of nebulised 
fluticasone propionate with oral prednisolone in children with an acute exacerbation of asthma.  The 
study demonstrated that nebulised fluticasone propionate is at least as effective as oral prednisolone in 
the treatment of children presenting with an acute exacerbation of asthma20.
JUSTIFICATION OF THE STUDY
 Corticosteroids have been have been used in the management of acute exacerbation of asthma25, 
27, 28. 
 Intravenous29  and oral  administration25 of  corticosteroids  have  been  used with good results, 
aside from some controversial findings for the intravenous route. 
 Oral administration was found to be equally effective to the intravenous route in the initial 
treatment of acute asthma.
 Data from some studies have suggested that intravenous and oral corticosteroids produce no 
immediate beneficial effects in the management of acute exacerbation of asthma30, 31.
 Inhaled  corticosteroids  have  greater  anti-inflammatory  and  antiasthma  potency  and  fewer 
systemic effects than oral corticosteroids and they are delivered directly into the lung.
 Furthermore recent research has revealed that inhaled corticosteroids produce rapid beneficial 
effects  (through non –genomic  action)  by causing vasoconstrictive effects  on the bronchial 
vasculature thereby relieving congestion in airways and potentiating the bronchodilator effects 
of inhaled β2 agonists5.
 Therefore Inhaled Corticosteroids are excellent candidate agents for controlling acute asthma. 
 Various inhaled corticosteroids have been used in acute asthma in numerous studies. Among 
these  agents  budesonide has  shown  to  be  more  effective  because  of  its  favourable  local 
pharmacokinetics and potent bronchial vasoconstrictive properties5, 6, 7.
 Some recent studies have investigated the effect of inhaled corticosteroids in the exacerbation 
of asthma, but their role in acute asthma and the preferred dose schedule for controlling acute 
attacks in children have not been established.
 In  a  meta-analysis  preformed  by  Rodrigo  and  Rodrigo4,  involving  seventeen  randomised 
controlled  trials,  it  has  been  shown  that  high  doses  of  inhaled  corticosteroids  had  rapid 
beneficial effects in improving pulmonary function thereby increasing early discharges.
 This is a very relevant finding since hospital admissions count for the largest part of direct 
health costs for asthma.
 Hence  the  present  study  is  aimed  at  evaluating  immediate  beneficial  effects  of  inhaled 
corticosteroids (budesonide) in the management of acute exacerbation of asthma in children (4 
– 12 yrs) in an Emergency Department setting.
AIM OF THE STUDY
To determine the early clinical benefit of Inhaled Corticosteroids (Nebulised Budesonide) for 
the treatment of children (4 – 12 yrs) with Acute Severe Asthma managed in the emergency department 
(ED) compared to Systemic Corticosteroids (oral prednisolone).
METHODS
The Study was designed as a Randomised double blind, placebo controlled trial  
and it was conducted at the Emergency Department of the Institute of Child Health & 
Hospital for Children, Chennai between the period of May 2007 to November 2008.
Setting and population
Known asthmatic children aged between 4 to 12 years of both sexes presenting with cough, cold 
and acute onset of breathlessness were initially screened after stabilising the child. Life-threatening 
presentations were excluded from the study.
INCLUSION CRITERIA
• Children  over  4  years  of  age  presenting  with  acute  exacerbation  of  asthma  to  the 
Emergency Department of the Institute of Child Health.
• Known case of asthma
Case definition for Acute Severe Asthma22.
EXCLUSION CRITERIA
Children with 
• congenital heart disease
• chronic lung disease
•  X-ray and/ clinical evidence of pneumonia
• Higher severities of asthma e.g. life threatening Asthma 
Subsequently the remaining children were subjected to X-ray. Those children having clinical/ 
X-ray evidence of pneumonia or cardiomegaly or other lung pathologies are excluded from the study. 
The remaining children were assessed for the severity of Asthma. Those children coming under the 
category of  Acute  Severe  Asthma (see  triangle  above)  were included in  the  study after  obtaining 
parental consent and informing the child. Children of those parents who didn’t give parental consent 
were excluded from the study.
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Randomisation
Opaque sealed envelopes containing labels A or B were developed and kept in the Emergency 
Department in a single box.
As soon as the child was recruited into the study one sealed envelope was opened and the child 
managed as per the group assigned in the envelope.
The  study  group  or  budesonide  group received  three  doses  of  nebulised  salbutamol  (0.15 
mg/kg) and budesonide respirator solution (800 μg) at intervals of 20 minutes and a single dose of 
placebo tablets. Similarly the control group or prednisolone group received three doses of nebulised 
salbutamol (0.15 mg/kg) along with placebo solution at intervals of 20 minutes and a single dose of 
oral  prednisolone (2 mg/kg) (see figure 11). The study and control groups were assessed every 20 
minutes for upto 1 hour. The parameters that were assessed include heart rate, respiratory rate, oxygen 
saturation, PEFR (Peak Expiratory Flow Rate) at  the end of one hour and at 4 hrs and fitness for 
discharge at the end of 2 hours.
Blinding
In this trial, children were assigned treatments at random and neither the subject nor the person 
delivering the drug and measuring the outcome know whether the subject received an active drug or a 
placebo. Hence it is double-blinded. 
The  study  group  or  budesonide  group received  three  doses  of  nebulised  salbutamol  (0.15 
mg/kg) and 3.2 ml of budesonide respirator solution (800 µg) at intervals of 20 minutes whereas the 
control or prednisolone group received three doses of nebulised salbutamol (0.15 mg/kg) along with 
3.2 ml of placebo respirator solution at intervals of 20 minutes. The placebo respirator solution and 
budesonide respirator solution were stored in dark brown containers that looked similar and labelled as 
either A or B. For example, if  the placebo respirator solution is labelled as A then the budesonide 
solution would be labelled as B and vice versa. So each patient received 3.2 ml of either the placebo 
solution or budesonide solution. This ensured that the study group patients received the appropriate 
dose  of  budesonide  i.e.  800µg  as  each  ml  of  budesonide  solution  contains  250µg  (hence  3.2  ml 
contains 800μg).
In the same manner the study group received placebo tablets (powdered) whereas the control 
group  received  prednisolone  tablets  (powdered)  which  had  similar  appearances.  To  avoid  bias  in 
administering the tablets, the prednisolone (5mg) tablets were powdered and stored in small plastic 
packets which were sealed tightly so that each packet contained 5 mg of prednisolone. Six such packets 
each  containing  5 mg of  prednisolone  were then  put  into  a  big  envelope  and sealed.  Thirty  such 
envelopes,  each  containing  six  packets  of  powdered  prednisolone  were  prepared  and  kept  in  the 
emergency department.   Similarly,  placebo powder  which had the same appearance as that  of  the 
prednisolone powder was packed similarly into small plastic packets six of which were then put into a 
big envelope. Thirty such envelopes, each containing six packets of placebo powder were prepared and 
kept  in  the  emergency  department.  The  prednisolone  and  the  placebo  envelopes  containing  six 
prednisolone or six placebo packets each respectively were then labelled as either A or B. For example, 
if the prednisolone envelopes were labelled as A then the placebo envelopes were labelled as B and 
vice versa.
The powdered  prednisolone  tablets  or  placebo tablets  were administered  orally after  initial 
stabilisation and before starting nebulisation. Thus children recruited into group A received 4 (4 – 6yrs) 
or 6 (6-12 yrs) packets from envelope A according to the age of the patient. Similarly children recruited 
into group B received 4 (4 – 6yrs) or 6 (6-12 yrs) packets from envelope B. This ensured that the 
children in control group received the appropriate dose of prednisolone (20 mg for 4-6 yrs, 30 mg for 
6-12 yrs). 
Thus  budesonide solution is  paired  with  placebo tablets  (powder) whereas  prednisolone  is  
paired with placebo respirator solution. For example if the budesonide solution was labelled as A, then 
the placebo tablets were labelled as A, whereas the prednisolone tablets and placebo solution were 
labelled  as  B.  So  children  assigned  A  would  have  got  budesonide  solution  and  placebo  powder, 
whereas children assigned B would have got prednisolone tablets and placebo solution. It is ensured 
that all patients in each group received both the nebuliser solution and tablets (powdered). In case any 
child deteriorated during the trial, the trial was discontinued and the child was managed as per the 
regular ER protocol for higher severities of asthma.
OUTCOME MEASURES
(All measured from 0-4 h of the protocol)
Primary outcome
1. Fitness for discharge at the end of 2 hrs, based upon clinical severity scoring system16 (a score 
of ≤ 0.4 is taken as fit for discharge, see table 2).
Secondary outcomes
1. Heart rate
2. Respiratory rate
3. Oxygen saturation
4. Peak expiratory flow rates (PEFR) (at 1 hr, 4 hrs)
5. Adverse effects
Table 2 -Clinical Scoring System26
Variable Score=0 Score=1
Heart rate  <120/min for > 5 yrs
<130/min for 2-5 yrs
>120/min for > 5 yrs
>130/min for 2-5 yrs
Respiratory rate  <50/min 2 – 5 yrs
<30/min for >5 yrs
>50/min 2-5 yrs
> 30/min for >5 yrs
Dyspnea  Absent or mild Moderate or severe
Accessory muscle use Absent or minimal Moderate or severe
Wheezing Absent or end expiratory only Throughout expiration or 
expiratory
Note:  the score was expressed by adding the number of positive values (i.e. score =1) for an individual 
patient,  as a fraction of the total  number of variables i.e. 5. The final score ranged from 0 to 1.0, 
increasing with severity.
SAMPLE SIZE
The primary outcome measure (fitness for discharge) was used to calculate the sample size. 
Assuming expected difference in improvement in discharge rates between Inhaled Corticosteroids and 
Systemic Corticosteroids to be 20%. Sample size was calculated with power of 80%, α error of 20% 
and β error of 5%. 
ALPHA ERROR 20%
BETA ERROR 5%
POWER 80%
SAMPLE SIZE 60
STATISTICAL ANALYSIS
Statistical  analysis  for  the  outcomes  were  done  by  using  Chi  square  test  for  fitness  for 
discharge, paired t-test for  parametric variables in each group and two-sample (unpaired) t-test for 
estimating difference in the improvement in parametric variables between the groups. A p value of less 
than 0.05 is considered as significant. 
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FIGURE 11 PROTOCOL FOR MANAGEMENT OF 
CHILDREN WITH ACUTE SEVERE ASTHMA RECRUITED 
INTO THE STUDY
RESULTS
Eighty  five  asthmatic  children  aged  between  4  –  12  years  presenting  to  the  emergency 
department with cough, cold and acute onset breathlessness were initially screened. Fifteen children 
with features of life-threatening asthma were excluded from the study. The rest of the children were 
subjected to an X-ray. Out of these, five children had X-ray evidence of bronchopneumonia who were 
then excluded from the study. Parents of four children declined consent. The remaining sixty one (61) 
children were recruited in to the study after obtaining consent. 
Thirty one (31) children were randomised into prednisolone group and thirty (30) children into 
budesonide group and treated accordingly (see figure 12).  The baseline characteristics  of both the 
groups were comparable as shown in table 5. These children were assessed at regular intervals of 20 
minutes for upto one hour for parameters like heart rate, respiratory rate and oxygen saturation. Peak 
Expiratory  Flow  Rates  were  done  at  the  end  of  1  hr  and  at  4  hrs.  Only  seventeen  children  in 
prednisolone group and eighteen children in budesonide group were able to perform FVC (Forced Vital 
Capacity) manoeuvre. Hence PEFRs were measured only in these children at the end of one hour and 
again at 4 hrs after starting treatment. The fitness for discharge was assessed at the end of 2 hrs using 
the clinical severity scoring system shown in table 2.  Children with a score of 0.4 or less were taken as 
fit for discharge.
FIGURE  12  TRIAL  PROFILE  OF  CHILDREN  PRESENTING  TO  THE 
EMERGENCY DEPARTMENT WITH ACUTE SEVERE ASTHMA
85 asthmatic children presented with cough, cold 
and acute onset breathlessness to the ED
24 did not take part
(20 were ineligible 
and
4 declined consent)
61 children randomly allocated 
treatment
31 children assigned prednisolone 
group
30 children assigned budesonide 
group
All 30 children completed study 
but PEFR measurable in 18 
children only
All 31 children completed study
PEFR measurable in 17 children 
only
Table 3 Demographic characteristics of patients on arrival at the Emergency 
Department
Age Groups Prednisolone group Budesonide groupBoys Girls Total Boys Girls Total
4 – 6 yrs 4 2 6 2 2 4
6 – 8 yrs 6 5 11 6 5 11
8 – 10 yrs 4 8 12 6 4 10
10 – 12 yrs 1 1 2 2 3 5
Total 15 16 31 16 14 30
Of the thirty one children recruited into prednisolone group fifteen were boys and sixteen were 
girls. Of the thirty children recruited into budesonide group sixteen were boys and fourteen were girls. 
There were six children between 4-6 yrs in prednisolone group and four children in the same age group 
in budesonide group. Similarly the numbers of children in other age groups were comparable between 
the two groups as shown in table 3.
DEMOGRAPHIC STATISTICS OF PREDNISOLONE 
GROUP
DEMOGRAPHIC STATISTICS OF BUDESONIDE 
GROUP
Table 4 Nutritional status
Weight for age %
Prednisolone 
group (n=31)
Budesonide group 
(n=30)
Normal (> 80 %) 23 18
Grade I PEM (71 – 80) 8 10
Grade II PEM (< 70 %) 1 2
Nutritional status of children participating in the study was assessed using the weight for age. 
According to Indian Academy of Pediatrics classification, one child in prednisolone group and two 
children in budesonide group had grade II PEM. Similarly, eight children in prednisolone group and ten 
children in budesonide group had grade I PEM. The remaining children in both the groups were of the 
normal weight for age. Thus both the prednisolone group and the budesonide group were comparable 
with respect to the nutritional status.
Table 5 Baseline comparison
Variable
Prednisolone group
n = 31
Budesonide group
n = 30
p value
Age 7.14 ± 1.93 7.8 ± 1.93 0.19
Sex (M : F) 15:16 17:13
Nutritional status (W/A) 83.74 ± 6.35 83.13 ± 8.82 0.76
Respiratory rate 53.81 ± 8.86 50.67 ± 6.02 0.112
Heart rate 148.19 ± 11.86 143.53 ± 11.66 0.127
O2 saturation 93.39 ±1.022 98.37 ± 1.098 0.940
PEFR (at 1 hr) (L/min) 185.88 ± 40.05 (n = 17) 180.56 ± 38.15 (n = 18) 0.69
Clinical Severity Scoring 0.677 ± 0.17 0.66 ± 0.18 0.69
As seen from the above table, children in both the groups were matched for categorical 
variables like age, sex and nutritional status (weight for age). Similarly both the groups were 
matched for continuous variables like initial heart rate, initial respiratory rate, initial oxygen 
saturation,  PEFR  at  one  hrs  and  clinical  severity  scoring  at  presentation  with  p values 
insignificant i.e. >0.05.
Comparison in the outcome measures
Heart rate
Children in both groups showed a progressive decrease in heart rate with treatment. The average 
initial heart rate for prednisolone group was 148.2 ± 11.86 which showed a significant decrease to an 
average heart rate of 123.42 ± 12.64 at 60 min (p < 0.001) (see table 6).
The  average  initial  heart  rate  for  budesonide  group  was  143.53  ±  11.66  which  decreased 
significantly to an average rate of 106.67 ± 9.94 at 60 min (p< 0.001) (see table 6).
Comparison analysis revealed that the decrease in HR in budesonide group (36.87 ± 10.86) was 
significantly greater than in prednisolone group (24.77 ± 13.0) (p < 0.001).
TABLE 6 Decrease in heart rate (HR)  in prednisolone and budesonide groups
GROUP AVERAGE INITIAL HR
AVERAGE HR AT 60 
MIN
p value
Prednisolone group 148.2 ± 11.86 123.42 ± 12.64 < 0.001
Budesonide group 143.53 ± 11.66 106.67 ± 9.94 < 0.001
DECREASE IN HEART  RATE IN PREDNISOLONE 
GROUP
DECREASE IN HEART  RATE IN BUDESONIDE 
GROUP
Respiratory rate
Progressive decrease in respiratory rate was noted in both treatment groups. The average initial 
respiratory rate for prednisolone group was 53.80 ± 8.86 which showed a significant decrease after 1 
hour of therapy to an average of 33.29 ± 9.63 (p < 0.001) (see table 7).
The average initial respiratory rate for budesonide group was 50.67 ± 6.02 which also decreased 
significantly to average rate of 28.60 ± 5.26  at 1 hour (p <0.001) (see table 7).
But  when  comparing  prednisolone  group  with  budesonide  group  there  was  no  significant 
difference in the decrease in respiratory rates noticed at 1 hr (p > 0.2).
TABLE 7 Decrease in respiratory rate (RR) in prednisolone and budesonide groups
GROUP AVERAGE INITIAL RR
AVERAGE RR AT 60 
MIN
p value
Prednisolone group 53.80 ± 8.86 33.29 ± 9.63 < 0.001
Budesonide group 50.67 ± 6.02 28.60 ± 5.26 < 0.001
CHANGE IN RESPIRATORY RATE IN 
PREDNISOLONE GROUP
CHANGE IN RESPIRATORY RATE IN BUDESONIDE 
GROUP
Oxygen Saturation
Improvements in oxygen saturation were noted in both the groups. The average initial saturation 
was 98.39 ± 1.02 for prednisolone group. This value increased to an average of 99.84 ± 0.37at 1 hr 
which is statistically significant with a p < 0.001 (see table 8).
In budesonide group the average initial saturation noted was 98.37 ± 1.09 and this increased 
significantly to an average of 99.77 ± 0.43 (p < 0.001) (see table 8).
When comparing both the groups no significant difference in the improvement in saturation was 
noted (p > 0.2).
TABLE 8 Increase  in Oxygen saturation in prednisolone and budesonide groups
GROUP
AVERAGE INITIAL SaO2 
*
AVERAGE SaO2 AT 60 
MIN
p value
Prednisolone group 98.39 ± 1.02 99.84 ± 0.37 < 0.001
Budesonide group 98.37 ± 1.09 99.77 ± 0.43 < 0.001
*  SaO2 – Oxygen saturation
MPROVEMENT IN OXYGEN SATURATION IN PREDNISOLONE 
GROUP
IMPROVEMENT IN OXYGEN SATURATION IN BUDESONIDE 
GROUP
Peak Expiratory Flow Rate
PEFR progressed differently in both the groups. The average initial PEFR was 185.88 ± 40.05 
for prednisolone group and increased significantly to an average of 202.65 ± 35.93 at 4 hrs (p < 0.001) 
(see table 9). 
Whereas, the average initial  PEFR for budesonide group was 180.56 ± 38.15 and increased 
significantly to an average of 210.83 ± 30.79 at 4 hrs (p < 0.001) (see table 9).
PEFR values showed greater improvement in budesonide group (30.28 ± 20.97) compared with 
prednisolone group (16.76 ± 11.17) which is significant with a p value <0.05.
TABLE 9  Improvement in PEFR*  in prednisolone and budesonide groups
GROUP
AVERAGE PEFR AT I 
HR
AVERAGE PEFR* AT 4 
HRS
p value
Prednisolone group 185.88 ± 40.0 202.65 ± 35.93 < 0.001
Budesonide group 180.56 ± 38.15 210.83 ± 30.79 < 0.001
* PEFR – Peak Expiratory Flow Rate
INCREMENT IN PEFR (PEAK EXPIRATORY FLOW RATE) IN 
PREDNISOLONE GROUP
INCREMENT IN PEFR IN BUDESONIDE GROUP
Fitness for discharge
The fitness  for discharge was based on the clinical  severity scoring shown in table  2.  The 
average baseline scores in both the groups were comparable (p = 0.69) as shown in table 5. Both groups 
showed a statistically significant improvement in clinical severity scores at the end of 2 hrs (p < 0.001). 
A score of 0.4 or less is taken as criteria for discharge. Based on this scoring system, sixteen out 
of thirty patients in budesonide group (16/30, 53%) and eight out of thirty one patients in prednisolone 
group (8/31, 26%) were fit for discharge at the end of 2 hrs. The proportion of patients who were fit for 
discharge at the end of 2 h was significantly higher in budesonide group than in the prednisolone group 
(53% vs. 26%). This difference in fitness for discharge rates is statistically significant with a p value of 
< 0.05 (see table 10). 
Table 10 Fitness for discharge in prednisolone group vs. budesonide group
GROUP
Fitness for discharge
YES NO
Budesonide group 16 14
Prednisolone group 8 23
FITNESS FOR DISCHARGE
Adverse effects
No clinically significant adverse effects were noted in both the groups. Similarly, deterioration 
during management requiring discontinuation of the trial did not happen in both the groups. It therefore 
seems  that  both  prednisolone  and  budesonide  can  be  used  safely  in  the  management  of  acute 
exacerbation of asthma.
Table 11 Comparison in the outcome measures between the groups
Outcome measure Prednisolone 
group
Budesonide 
group
p value
Decrease in Heart rate* 24.77 ± 13.0 36.87 ± 10.86 < 0.001
Decrease in 
Respiratory rate*
20.51 ± 6.73 22.07 ± 5.62 0.33
Improvement in 
Oxygen Saturation*
1.452 ±0.89 1.4 ± 0.81 0.81
Increment in PEFR# 16.76 ± 11.17 30.28 ± 20.97 < 0.05
Fitness for discharge$ 53% 26% < 0.05
*  at the end of 60 minutes
#   at the end of 4 hrs
$    at the end of 2 hrs
Children in budesonide group had greater decrease in heart rate compared with prednisolone 
group (p < 0.001). Similarly children in budesonide group also showed greater improvement in PEFR 
(peak  expiratory  flow  rate)  compared  with  prednisolone  group  (p <  0.05).  But  no  statistically 
significant difference was noted between the groups with respect to change in respiratory rate and 
oxygen  saturation.  The  proportion  of  patients  who  were  fit  for  discharge  at  the  end  of  2  h  was 
significantly higher  in  budesonide group than in  the prednisolone group (53% vs.  26%), which is 
statistically significant with a p value < 0.05 (see table 11).

MANAGEMENT OF ACUTE EXACERBATION OF ASTHMA IN THE 
EMERGENCY DEPARTMENT
\PEAK EXPIRATORY FLOW RATE MEASUREMENT IN A YOUNG CHILD
DISCUSSION
Inhaled  glucocorticoid  therapy  is  primarily  used  for  asthma  prophylaxis.  Its  use  in  acute 
exacerbation has not been fully evaluated because this form of glucocorticoid was believed to have 
minimal immediate activity. However, the rapid effect of nebulised budesonide has been demonstrated 
in both chronic and acute asthma. Several studies involving stable asthmatic patients showed improved 
spirometry within 1 hour of budesonide administration, with duration of effect between 5 and 12 hours. 
The results revealed statistically significant improvement in vital signs (heart rate, respiratory 
rate),  oxygen saturation,  Peak Expiratory Flow rates  (PEFR) and clinical  scores  in  both the study 
(budesonide) and control (prednisolone) groups at  the end of treatment.  There is also a significant 
increase  in  fitness  for  discharge  rates  at  the  end  of  2  hrs  in  budesonide  group  compared  with 
prednisolone group.
Comparison analysis showed significantly greater decrease in heart rate in budesonide group 
compared with prednisolone group at the end of treatment. Similarly statistically significant difference 
is peak expiratory flow rate increments between the study and control groups are noted at the end of 4 
hrs. Children in budesonide group showed significantly greater improvement in PEFR compared with 
prednisolone group at the end of 4 hrs.
Children in both groups also had a significant decrease in respiratory rate at the end of three 
doses of nebulisation. However, no significant difference in improvement is noted between the groups. 
Hence  it  is  concluded  that  both  groups  showed  equal  improvement  with  respect  to  decrease  in 
respiratory rates.
Similarly  oxygen  saturation  improved  significantly  at  the  end  of  treatment  in  both  the 
prednisolone and budesonide groups. However, there is no significant difference in the improvement 
noted between the groups.
Both the treatment groups showed significant improvement in clinical scores at the end of two 
hours of treatment. Consequently fitness for discharge rates increased in both the groups. However, the 
fitness for discharge rates  was significantly high in budesonide group compared with prednisolone 
group. This favours an early effect of high doses of inhaled budesonide at short intervals of 20 minutes 
on increasing the number of discharges.
The Number Needed to Treat (NNT) is calculated at 3.85 i.e. approximately 4, which means 
that 4 children are needed to be treated with nebulised budesonide to provide one additional clinical 
benefit  i.e.  one additional increase in discharge rate.  This is a very relevant finding since hospital 
admissions count for the largest part of direct health costs for asthma.
Over the past decade, it  has become increasingly recognized that airways inflammation is a 
major  component  of  asthma.  Due to  their  potent  anti-inflammatory effects,  therapy with  systemic 
corticosteroids (oral, IM, or IV) is recommended in all patients presenting to the emergency department 
with an acute exacerbation of asthma. Furthermore, a short course of oral corticosteroids following 
emergency department discharge significantly reduces the number of relapses and the amount of ß-
agonist use without an increase in side effects. 
Many studies have suggested that the administration of parenteral corticosteroids (oral, IM, or 
IV) in addition to inhaled ß2-agonists in patients with acute asthma on their arrival at the emergency 
department neither improved airflow obstruction nor reduced the need for hospitalization. This effect 
may be due to the fact that it may take up to 24 h for the effects of corticosteroids to become evident.
In  a  meta-analysis  preformed  by  Rodrigo  and  Rodrigo,  involving  seventeen  randomised 
controlled trials,  it  has been shown that  high doses of  inhaled corticosteroids  had rapid beneficial 
effects in improving pulmonary function thereby increasing early discharges. 
They have shown that  administration of high doses of inhaled corticosteroids together with 
salbutamol in patients with acute asthma who were treated in the emergency department significantly 
improved pulmonary function when compared to the use of salbutamol alone or a combination of 
salbutamol with prednisolone. 
Trials  that  used single doses of inhaled corticosteroids or multiple doses in very prolonged 
intervals  presented  smaller  beneficial  effects  or  no  difference  between  the  groups.  So,  the  most 
important fact would not be the total dose administered, but rather the relationship between the dose 
and timing of administration. Hence the benefit is seen only when high doses are repeated at short 
intervals of less than 30 minutes. It is important to note that this benefit is evident within 90 min which 
may be helpful in early discharge thereby cutting down the costs of acute asthma management. It has 
been  already  suggested  that  locally  acting  (inhaled)  corticosteroids  act  by  causing  local 
vasoconstriction and thereby decreasing edema formation and plasma exudation.
The economic cost of asthma is considerable both in terms of direct medical costs (such as 
hospital admissions and cost of pharmaceuticals) and indirect medical costs (such as time lost from 
work and premature death)3. It is therefore suggested that early use of inhaled corticosteroids in acute 
exacerbation of asthma may greatly reduce both the direct and indirect medical costs.
CONCLUSION
 Nebulised  Budesonide  has  definite  early  clinical  benefit  in  management  of  Acute  Severe 
Asthma. 
 Significant improvement in vital signs (decrease in heart rate and respiratory rate) and oxygen 
saturation were noted at the end of one hour of treatment with nebulised budesonide.
 Inhaled budesonide also improved pulmonary function as measured by Peak Expiatory Flow 
Rate (PEFR) at the end of 4 hours of treatment.
 Inhaled  Budesonide  produced  greater  improvement  in  heart  rate  and  pulmonary  function 
(PEFR) compared with oral prednisolone.
 Though cost factor was not considered in the analysis, an overall view has shown that twice the 
numbers  of  children  were  fit  for  discharge  in  the  Budesonide  group when  compared  with 
Prednisolone group.
 This  effect  is  particularly  evident  when  high  doses  (800  μg)  of  inhaled  Budesonide  are 
administered along with inhaled β2  agonists (salbutamol) and repeated at short intervals of 20 
minutes for upto 3 doses.
RECOMMENDATION
Hence in a resource poor setting like ours, use of nebulised budesonide in 
the  management  of  acute  severe  asthma  is  recommended  as  it  produces 
favourable benefits by
 reducing the number of admissions
 reducing the social dislocation due to hospital admissions
 reducing the untoward side effects of prednisolone use
 reducing the costs for the patient and the hospital
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